Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Current Assets (2016 - 2025)

IGC Pharma (IGC) has disclosed Current Assets for 15 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • Quarterly Current Assets fell 52.85% to $2.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Sep 2025, down 52.85% year-over-year, with the annual reading at $2.9 million for FY2025, 21.84% down from the prior year.
  • Current Assets for Q3 2025 was $2.0 million at IGC Pharma, down from $2.2 million in the prior quarter.
  • The five-year high for Current Assets was $23.5 million in Q1 2021, with the low at $2.0 million in Q3 2025.
  • Average Current Assets over 5 years is $9.4 million, with a median of $6.1 million recorded in 2023.
  • The sharpest move saw Current Assets soared 68.44% in 2021, then plummeted 61.7% in 2023.
  • Over 5 years, Current Assets stood at $19.2 million in 2021, then tumbled by 51.37% to $9.4 million in 2022, then tumbled by 61.7% to $3.6 million in 2023, then fell by 14.85% to $3.1 million in 2024, then crashed by 34.32% to $2.0 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $2.0 million, $2.2 million, and $2.9 million for Q3 2025, Q2 2025, and Q1 2025 respectively.